Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) fell NaN on Wednesday . The company traded as low as $2.13 and last traded at $0.00. 742,104 shares changed hands during mid-day trading, an increase of Infinity from the average session volume of 0 shares.
A number of research firms have recently weighed in on INFI. ValuEngine upgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. Zacks Investment Research upgraded shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 17th. Finally, Wells Fargo & Company upgraded shares of Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Thursday, October 12th.
Infinity Pharmaceuticals (NASDAQ:INFI) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.12). During the same quarter in the prior year, the business earned $1.05 EPS.
In other news, insider Value Fund L. P. Biotechnology acquired 1,600,046 shares of the company’s stock in a transaction on Wednesday, October 4th. The shares were bought at an average cost of $1.26 per share, with a total value of $2,016,057.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 6.81% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Zacks Investment Management purchased a new stake in shares of Infinity Pharmaceuticals during the 2nd quarter worth $101,000. Highbridge Capital Management LLC purchased a new stake in shares of Infinity Pharmaceuticals during the 1st quarter worth $106,000. Ameriprise Financial Inc. purchased a new stake in shares of Infinity Pharmaceuticals during the 2nd quarter worth $130,000. LMR Partners LLP purchased a new stake in shares of Infinity Pharmaceuticals during the 2nd quarter worth $222,000. Finally, Wells Fargo & Company MN boosted its position in shares of Infinity Pharmaceuticals by 144.6% during the 1st quarter. Wells Fargo & Company MN now owns 81,493 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 48,177 shares in the last quarter. 67.14% of the stock is currently owned by institutional investors.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
What are top analysts saying about Infinity Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Infinity Pharmaceuticals Inc. and related companies.